ImmunityBio's FDA Application Acceptance Boosts Shares by 9%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Fool
- FDA Application Approval: ImmunityBio announced that its supplemental biologics license application has been accepted for FDA review, potentially leading to a label expansion for its core treatment Anktiva, resulting in a 9% stock price increase, reflecting market optimism about its future potential.
- Market Expansion Opportunity: The new application expands Anktiva's indications to treat BCG-unresponsive non-muscle invasive bladder cancer patients with papillary disease, which could significantly increase the target market, as approximately 85% of the 64,000 NMIBC patients diagnosed annually present with papillary disease.
- Insurance Coverage Outlook: FDA approval would prompt insurers to cover the treatment costs for Anktiva, further enhancing market acceptance and strengthening ImmunityBio's competitive position in the biopharmaceutical sector.
- Future Development Plans: ImmunityBio's clinical trial pipeline spans various diseases, including lung and ovarian cancer; although the stock has quadrupled, investors should remain cautious and consider phased investments to capitalize on future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.740
Low
5.00
Averages
7.33
High
9.00
Current: 7.740
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's ANKTIVA Therapy Economic Analysis Reveals Significant Cost Savings
- Significant Cost Savings: ImmunityBio's analysis indicates that ANKTIVA plus BCG can save up to $151,438 per cystectomy avoided in a U.S. Medicare population, highlighting the therapy's potential to reduce healthcare expenditures.
- Comparative Efficacy Advantage: The complete response rate for ANKTIVA plus BCG stands at 49.6%, surpassing TAR-200's 45.9%, while also incurring lower treatment and administration costs, showcasing ANKTIVA's competitive edge in treating BCG-unresponsive NMIBC patients.
- Economic Model Support: The findings are derived from a cost-consequence model utilizing data from ImmunityBio's QUILT-3.032 study and TAR-200's SunRISe-1 trial, emphasizing the potential of ANKTIVA plus BCG to deliver durable responses while lowering costs to the healthcare system.
- Optimistic Investor Sentiment: ImmunityBio's stock has surged 291% year-to-date and 192% over the past 12 months, reflecting a positive investor reaction to the economic analysis results and indicating strong market confidence in the company's future growth.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Lawsuit Context: The class action lawsuit seeks to represent investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws, with Hagens Berman investigating claims and urging affected investors to come forward.
- Promotional Material Issues: The FDA criticized ImmunityBio's promotional materials for misleading the public by suggesting Anktiva could cure all cancers, while it is only approved for non-muscle invasive bladder cancer, emphasizing the lack of data supporting such efficacy claims, which poses serious public health risks.
- Investor Alert: Hagens Berman encourages investors to report their losses and warns knowledgeable individuals to consider assisting in the investigation, indicating significant challenges for the company regarding transparency and compliance, which could lead to broader legal and financial repercussions.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, 2026, and failure to act may result in lost compensation opportunities.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, leading to investor losses when the truth emerged, potentially impacting the company's reputation and stock performance.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against ImmunityBio in the Central District of California on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026, alleging false and misleading statements during this period.
- Allegations of Misrepresentation: The lawsuit claims that CEO Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading statements about ImmunityBio's business and prospects, causing investors to suffer damages when the truth emerged.
- Investor Rights Protection: Affected investors must apply by May 26, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to encourage investors to reach out for assistance.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, with extensive experience in protecting investor rights and a commitment to serving clients across federal and state courts.
See More
Lowey Dannenberg Investigates ImmunityBio for Potential Securities Violations
- Investigation Launched: Lowey Dannenberg P.C. is investigating ImmunityBio Inc. for potential violations of federal securities laws, particularly allegations against the company and its executives for materially overstating Anktiva's capabilities, which may have misled investors.
- Lawsuit Context: A complaint filed on March 26, 2026, claims that Defendant Soon-Shion failed to disclose critical information throughout the class period, resulting in materially false and misleading statements about the company's business and prospects.
- Investor Losses: Attorney Andrea Farah stated that the investigation focuses on whether the company and its executives provided investors with accurate and complete information, urging those who suffered losses exceeding $50,000 in ImmunityBio securities to participate in the investigation.
- Law Firm Background: Lowey Dannenberg is a national firm representing investors who have suffered financial losses due to corporate fraud and malfeasance, with significant experience in prosecuting multi-million-dollar lawsuits and having recovered billions for investors.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Announcement: On May 22, 2026, Kessler Topaz Meltzer & Check, LLP announced a securities fraud class action against ImmunityBio, Inc. (NASDAQ:IBRX) for investors who purchased shares between January 19 and March 24, 2026, highlighting serious concerns about the company's financial health.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, leading to investor misconceptions about the company's prospects, which could adversely affect its stock price and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by its executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, demonstrating the direct impact of regulatory risks on the company's valuation.
- Investor Action Recommendation: Investors are advised to apply for lead plaintiff status in the class action by May 26, 2026, to represent all affected investors, indicating that the legal risks faced by the company could lead to broader financial losses.
See More
ImmunityBio's ANKTIVA Therapy Economic Analysis Reveals Significant Cost Savings
- Significant Cost Savings: ImmunityBio's analysis indicates that ANKTIVA plus BCG can save up to $151,438 per cystectomy avoided in a U.S. Medicare population, highlighting the therapy's potential to reduce healthcare expenditures.
- Comparative Efficacy Advantage: The complete response rate for ANKTIVA plus BCG stands at 49.6%, surpassing TAR-200's 45.9%, while also incurring lower treatment and administration costs, showcasing ANKTIVA's competitive edge in treating BCG-unresponsive NMIBC patients.
- Economic Model Support: The findings are derived from a cost-consequence model utilizing data from ImmunityBio's QUILT-3.032 study and TAR-200's SunRISe-1 trial, emphasizing the potential of ANKTIVA plus BCG to deliver durable responses while lowering costs to the healthcare system.
- Optimistic Investor Sentiment: ImmunityBio's stock has surged 291% year-to-date and 192% over the past 12 months, reflecting a positive investor reaction to the economic analysis results and indicating strong market confidence in the company's future growth.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading efficacy claims made by Chairman Soon-Shiong regarding Anktiva, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Lawsuit Context: The class action lawsuit seeks to represent investors who purchased ImmunityBio securities between January 19 and March 24, 2026, alleging violations of federal securities laws, with Hagens Berman investigating claims and urging affected investors to come forward.
- Promotional Material Issues: The FDA criticized ImmunityBio's promotional materials for misleading the public by suggesting Anktiva could cure all cancers, while it is only approved for non-muscle invasive bladder cancer, emphasizing the lack of data supporting such efficacy claims, which poses serious public health risks.
- Investor Alert: Hagens Berman encourages investors to report their losses and warns knowledgeable individuals to consider assisting in the investigation, indicating significant challenges for the company regarding transparency and compliance, which could lead to broader legal and financial repercussions.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, 2026, and failure to act may result in lost compensation opportunities.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, leading to investor losses when the truth emerged, potentially impacting the company's reputation and stock performance.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource capabilities in handling such cases.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against ImmunityBio in the Central District of California on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026, alleging false and misleading statements during this period.
- Allegations of Misrepresentation: The lawsuit claims that CEO Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in misleading statements about ImmunityBio's business and prospects, causing investors to suffer damages when the truth emerged.
- Investor Rights Protection: Affected investors must apply by May 26, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to encourage investors to reach out for assistance.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, with extensive experience in protecting investor rights and a commitment to serving clients across federal and state courts.
See More
Lowey Dannenberg Investigates ImmunityBio for Potential Securities Violations
- Investigation Launched: Lowey Dannenberg P.C. is investigating ImmunityBio Inc. for potential violations of federal securities laws, particularly allegations against the company and its executives for materially overstating Anktiva's capabilities, which may have misled investors.
- Lawsuit Context: A complaint filed on March 26, 2026, claims that Defendant Soon-Shion failed to disclose critical information throughout the class period, resulting in materially false and misleading statements about the company's business and prospects.
- Investor Losses: Attorney Andrea Farah stated that the investigation focuses on whether the company and its executives provided investors with accurate and complete information, urging those who suffered losses exceeding $50,000 in ImmunityBio securities to participate in the investigation.
- Law Firm Background: Lowey Dannenberg is a national firm representing investors who have suffered financial losses due to corporate fraud and malfeasance, with significant experience in prosecuting multi-million-dollar lawsuits and having recovered billions for investors.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Announcement: On May 22, 2026, Kessler Topaz Meltzer & Check, LLP announced a securities fraud class action against ImmunityBio, Inc. (NASDAQ:IBRX) for investors who purchased shares between January 19 and March 24, 2026, highlighting serious concerns about the company's financial health.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, leading to investor misconceptions about the company's prospects, which could adversely affect its stock price and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by its executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, demonstrating the direct impact of regulatory risks on the company's valuation.
- Investor Action Recommendation: Investors are advised to apply for lead plaintiff status in the class action by May 26, 2026, to represent all affected investors, indicating that the legal risks faced by the company could lead to broader financial losses.
See More
